Wickramasekara: Benchling will eventually expand into drug manufacturing software
Sajith Wickramasekara · Mastering Your Data with Sajith Wickramasekara · Dec 12, 2024 · at 24:30
Sajith Wickramasekara, CEO and co-founder of Benchling, outlines the company's eventual roadmap expansion beyond research and development.
0:00 / 0:05exact quote · 5.8s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“We've started to get our foothold in, in development. Like, someday we'll be in parts of manufacturing.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Sajith Wickramasekara
Wickramasekara: 60% of Benchling customers' laboratory instruments are unconnected
“The last time we kind of ran one of these benchmarking exercises was that For our customers, 60% of their instruments are not connected.”
Wickramasekara: Vertical software markets are less competitive, risking loss of focus
“One thing actually that's probably worse about vertical companies is you, the markets are not as competitive as horizontal companies, and so you can get a little unfocused at times”
Wickramasekara: Biologics and advanced modalities now dominate biopharma pipelines
“Biologics, advanced modalities are now majority of the pipeline. We actually have approved cell therapies, gene therapies. We're the first gene editing medicines approved.”
Wickramasekara: Pharma researchers do not lack tech literacy
“I think there's sometimes this, like, unfair caricature that people in pharma, like, don't know how to turn on a computer and that the industry just, like, doesn't believe in technology and so forth. I don't think belief in the technology is, like, lacking. I …”
Wickramasekara: Biological research software requires highly flexible data models
“The data and the technological needs of serving biology are very, very different. You have an incredibly complex multidimensional data model that's happening while the instrumentation lab is now, you know, vastly generating more, more data than ever, ever befo…”